BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kjeldsen J, Nielsen J, Ellingsen T, Knudsen T, Nielsen RG, Larsen MD, Lund K, Nørgård BM. Outcome of COVID-19 in hospitalized patients with chronic inflammatory diseases. A population based national register study in Denmark. J Autoimmun 2021;120:102632. [PMID: 33812171 DOI: 10.1016/j.jaut.2021.102632] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Creemers RH, Rezazadeh Ardabili A, Jonkers DM, Leers MPG, Romberg-Camps MJ, Pierik MJ, van Bodegraven AA. Severe COVID-19 in inflammatory bowel disease patients in a population-based setting. PLoS One 2021;16:e0258271. [PMID: 34610041 DOI: 10.1371/journal.pone.0258271] [Reference Citation Analysis]
2 Kjeldsen S, Nielsen J, Mertz Nørgård B, Kjeldsen J. Mesalazine in Inflammatory Bowel Disease and COVID-19: Hospitalization and Adverse In-Hospital Outcomes Based on Nationwide Data. Inflamm Bowel Dis 2021:izab299. [PMID: 34849917 DOI: 10.1093/ibd/izab299] [Reference Citation Analysis]
3 Bukhari M. A deeper dive into rare autoimmune diseases, death and COVID-19 in the first wave of the pandemic. Rheumatology (Oxford) 2021:keab898. [PMID: 34888623 DOI: 10.1093/rheumatology/keab898] [Reference Citation Analysis]
4 Nørgård BM, Zegers FD, Nielsen J, Kjeldsen J. Post COVID-19 hospitalizations in patients with chronic inflammatory diseases - A nationwide cohort study. J Autoimmun 2021;125:102739. [PMID: 34757259 DOI: 10.1016/j.jaut.2021.102739] [Reference Citation Analysis]
5 Bakasis AD, Mavragani CP, Boki KA, Tzioufas AG, Vlachoyiannopoulos PG, Stergiou IE, Skopouli FN, Moutsopoulos HM. COVID-19 infection among autoimmune rheumatic disease patients: Data from an observational study and literature review. J Autoimmun 2021;123:102687. [PMID: 34311142 DOI: 10.1016/j.jaut.2021.102687] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Deputy M, Sahnan K, Worley G, Patel K, Balinskaite V, Bottle A, Aylin P, Burns EM, Hart A, Faiz O. The use of, and outcomes for, inflammatory bowel disease services during the Covid-19 pandemic: a nationwide observational study. Aliment Pharmacol Ther 2022. [PMID: 35132663 DOI: 10.1111/apt.16800] [Reference Citation Analysis]
7 Boekel L, Hooijberg F, Vogelzang EH, Besten YR, Leeuw M, Atiqi S, van Vollenhoven RF, Wijbrandts CA, Gerritsen M, Krieckaert C, Dijkshoorn B, Bakhlakh S, Crooijmans JJ, Voskuyl A, van der Horst-Bruinsma IE, Lems W, Kuijpers TW, van Ham SM, Wieske L, Eftimov F, Kummer LY, van Dam PK, Stalman EW, Steenhuis M, Keijzer S, Cristianawati O, Keijser J, Loeff FC, Tas SW, Nurmohamed MT, Boers M, Rispens T, Wolbink G. Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study. RMD Open 2022;8:e002035. [PMID: 35383121 DOI: 10.1136/rmdopen-2021-002035] [Reference Citation Analysis]
8 Jung Y, Kwon M, Choi HG. Association between previous rheumatoid arthritis and COVID-19 and its severity: a nationwide cohort study in South Korea. BMJ Open 2021;11:e054753. [PMID: 34620675 DOI: 10.1136/bmjopen-2021-054753] [Reference Citation Analysis]